Proposed mRNA Covid-19 vaccine trial stalls over indemnity risk
09 June 2021 - 19:42
Top vaccine researchers have asked the government to step in and take on the indemnity risk for an international clinical trial that aims to determine the efficacy of Moderna’s mRNA coronavirus vaccine against strains circulating in Africa, as well as in people living with HIV.
A $130m (R1.77bn) trial funded by the US National Institutes of Health is ready to launch in eight African countries, including SA, but has stalled because the two companies that manufacture mRNA vaccines, Moderna and Pfizer, are unwilling to provide their shots, according to a report published in Science Magazine at the weekend...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.